You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 62 No. 4, April 2005 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (17)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Multiple Sclerosis/ Demyelinating Disease
 •Immunologic Disorders
 •Alert me on articles by topic

Metabolite Changes in Normal-Appearing Gray and White Matter Are Linked With Disability in Early Primary Progressive Multiple Sclerosis

J. Sastre-Garriga, MD; G. T. Ingle, MRCP; D. T. Chard, MRCP; Lí. Ramió-Torrentà, MD; M. A. McLean, PhD; D. H. Miller, FRCP; A. J. Thompson, FRCP

Arch Neurol. 2005;62:569-573.

Background  Abnormalities in normal-appearing brain tissues may contribute to disability in primary progressive multiple sclerosis (PPMS), where few lesions are seen on conventional imaging.

Objectives  To evaluate the mechanisms underlying disease progression in the early phase of PPMS by measuring metabolite concentrations in normal-appearing white matter (NAWM) and cortical gray matter (CGM) and to assess their relationship with clinical outcomes.

Design  Case-control study.

Setting  Tertiary referral hospital.

Patients  Forty-three consecutive patients within 5 years of onset of PPMS and 44 healthy control subjects.

Main Outcome Measures  Concentrations of choline-containing compounds, phosphocreatine, myo-inositol, total N-acetyl-aspartate (tNAA), and glutamate-glutamine were estimated using proton magnetic resonance spectroscopic imaging. Brain parenchymal, white matter and gray matter fractions and proton density and gadolinium-enhancing lesion loads were calculated. The Expanded Disability Status Scale and Multiple Sclerosis Functional Composite scores were recorded.

Results  In CGM, concentrations of the tNAA (P<.001) and glutamate-glutamine (P = .005) were lower in patients with PPMS than in controls. In NAWM, myo-inositol levels were higher (P = .002) and tNAA levels were lower (P = .005) in patients with PPMS than in controls. The Expanded Disability Status Scale score correlated with the tNAA concentration in CGM (r = –0.44; P = .03) and with myo-inositol (r = 0.41; P = .01) and glutamate-glutamine concentrations (r = 0.41; P = .01) in NAWM. Proton density lesion load correlated negatively with CGM tNAA concentration and positively with NAWM myo-inositol concentration.

Conclusion  Metabolite changes, which differ in CGM and NAWM, occur in early PPMS and are linked with disability.


Author Affiliations: Institute of Neurology, London, United Kingdom.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.